TECHWIRE 30
(CIX: WRAL30)  1,215.71    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: Apple)  132.05    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NY: QUINTILES)  70.52    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(OP: BASF SE)  94.49    (0 %)  Updated: 05:20 PM EDT, May 27 2015
(NQ: BioCryst)  11.32    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: BioDelivery)  7.95    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: CEMP)  36.56    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: Cisco Systems)  29.31    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: Cree)  30.04    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: DARA)  0.74    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NY: EMC CORPORATION)  26.69    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(NQ: Extreme Networks)  2.65    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: FB)  80.55    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NY: GLAXOSMITHKLINE)  44.61    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(NQ: GOOG)  539.79    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NY: IBM)  172.00    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(NY: LH)  119.45    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(OP: Lenovo Group)  32.28    (0 %)  Updated: 05:20 PM EDT, May 27 2015
(NY: MRK)  59.46    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(NQ: Microsoft Corp)  47.61    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: NTAP)  33.02    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NY: NOVARTIS AG)  103.53    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(OP: Novozymes A/S)  47.82    (0 %)  Updated: 05:20 PM EDT, May 27 2015
(NY: PFIZER)  34.30    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(NQ: Pozen)  6.72    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NY: RED HAT)  78.48    (0 %)  Updated: 06:40 PM EDT, May 27 2015
(NQ: BBRY)  10.11    (0 %)  Updated: 08:10 PM EDT, May 27 2015
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  15.32    (0 %)  Updated: 08:10 PM EDT, May 27 2015

Posts tagged “GSK”

May 20

Premium Lock 'Introducing PfizerKline'? Wall Street analysts sees Pfizer buying GSK

Pfizer  Where there is smoke is there fire when it comes to rumors that Pfizer might try to buy troubled GlaxoSmithKline? A Wall Street analyst is the latest to speculate that a mega merger could be in the works.

Updated May 11

GSK, UNC-Chapel Hill form company to seek HIV cure

Drug giant GlaxoSmithKline is teaming up with the University of North Carolina at Chapel Hill in an attempt to find a cure for AIDS. The two will form a new company called Qura Therapeutics and will launch an "HIV Cure Center" in Chapel Hill. GSK is committing $20 million over the next five years to fund the project.

May 7

New GSK board chair expresses support for CEO Witty

GSK's HQ in London           The new executive chair of GlaxoSmithKline came out in support of CEO Andrew Witty on Thursday, a day after Witty disclosed his strategy for bolstering the drug giant's future. "Andrew has the complete support of the board," said Philip Hampton. GSK also disclosed its new board lineup.

Updated May 7

GSK won't spin off its HIV business, cuts Novartis deal return to shareholder

Andrew Witty      As a new chair prepares to take over at GlaxoSmithKline, the drug giant says it will not spin off its majority holdings in a promising HIV drug developer. CEO Andrew Witty also says GSK won't return as much of the profits from its big deal with Novartis to shareholders.

May 1

FDA approves expansion of GSK inhaler to fight asthma

GSK   ​GlaxoSmithKline has received U.S. approval to sell its once-a-day respiratory inhaler Breo Ellipta for a new use in asthma patients ages 18 and older.

April 30

Quintiles, Biogen, Martin Marietta, GSK, Pfizer, Merck crack InformationWeek elite list

InformationWeek's annual "Elite 100" corporate list for innovative technology includes several located in or have big operations around the Triangle as well as the City of Asheville.

The Elite 100 The Elite 100

Updated April 30

Uber eyes deliveries; IBM' quantum computing advance; Yahoo CEO pay surges; GSK targets shingles; genetic testing for insurance?

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Uber eyes making deliveries; IBM reports an advance in quantum computing; pay for Yahoo CEO surges; GSK's shingles drug shows promise; and are genetic tests for insurance in your future?

April 27

Premium Lock Report: 'Strong likelihood' Pfizer may try to acquire GSK

Pfizer  Drug giant Pfizer, which failed a year ago in its attempt to acquire AstraZeneca, may now be targeting GlaxoSmithKline as a takeover target, according to business news site BidnessEtc. Pfizer has steadily increased its North Carolina presence in recent years, and GSK employs thousands in the Triangle.

April 24

Premium Lock GSK malaria vaccine nearer OK; Aerie not giving up on glaucoma treatment; Duke Energy's Greentech award; Novartis soars; CDC's new tech tracks listeria

Bulldog In the latest wrapup of technology and life science news: GSK's malaria vaccine is closer to approval after clinical trial; Aerie Pharmaceuticals not giving up on glaucoma treatment; Duke Energy wins a Greentech award; Novartis soars in wake of GSK, Eli Lilly deals; CDC uses new tech to track listeria illnesses.

April 16

Premium Lock Report: GSK shutting Pittsburgh office, eliminating 274 jobs

Layoffs        Drug giant GlaxoSmithKline, which already is cutting hundreds of jobs in the Triangle and in the Philadelphia area, is now in the process of closing an office in Pittsburgh where 274 people work, according to the Pittsburgh Business Times.

April 13

Premium Lock GSK considers revamping compensation plan for sales force

GSK   Drug giant GlaxoSmithKline is considering making changes in the way its sales force is compensated, according to an internal memo obtained by Bloomberg News and The Wall Street Journal.

April 3

Premium Lock GSK picks Maryland for vaccine research and development center

Drug giant GlaxoSmithKline, which is laying off hundreds of people in Research Triangle Park and Pennsylvania, is going to build a new research and development center for vaccines in Maryland.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

Updated March 25

Premium Lock Google Fiber expands; Jim Goodnight's venture play; non-GMO food label; new Instagram app; GSK's next HQ in Asia

Bulldog Bulletin In today's Bulldog wrapup of technology and life science news: Google Fiber is expanding; Jim Goodnight's new venture play is biotech; a proposed label for non-GMO foods; Instagram has a new app; and GSK is building a new Asian headquarters.

March 25

Premium Lock Life beyond GSK: The entrepreneurial career options

Biotech   At an event put on by the North Carolina Biotechnology Center and supported by GlaxoSmithKline, more than 300 people who are losing their jobs at GSK through layoffs gathered to hear about possible options for future employment. "There is life beyond GSK," former GlaxoWellcome CEO Robert Ingram tells the crowd.

Updated March 23

Premium Lock Glaxo plans 180 layoffs in Durham

GSK's HQ in London GlaxoSmithKline notified the state Monday that it plans to eliminate 180 jobs at its Durham offices effective June 1.

Tags: Layoffs, GSK
March 20

Premium Lock Despite Bill Gates' warning, will world prepare for the next Ebola?

Bill Gates The Bill & Melinda Gates Foundation took a major role in trying to find a vaccine to treat Ebola, even providing funding to Durham-based Chimerix. Now, Bill Gates is warning that the world must prepare for future epidemics. If we are smart, we will listen and learn from what's happened from an outbreak that has killed some 10,000 people.

March 20

Premium Lock AT&T's $40M error; GSK job cuts; Amazon 1-hour delivery; Salix $78M parachutes; GSK inhaler; China freedom group attacked

Bulldog In today's Bulldog wrapup of technology and life science news: AT&T takes a $40M hit in a lawsuit; GSK is cutting 150 jobs in Pa.; Amazon expands 1-hour delivery service; Salix handing out $78M in golden parachutes; GSK wins OK for inhaler; and a China web freedom group is under attack.

March 19

Premium Lock GSK exec: 'Social responsibility' led to Ebola project

Ebola A senior executive at troubled drug giant GlaxoSmithKline says "social responsibility" is a major reason for its attempts to develop a vaccine to treat Ebola. Resources were diverted from other projects to support the Ebola fight, he says.

March 18

Premium Lock GSK invests $25M in global Alzheimer's venture fund

Brain power  GlaxoSmithKline, Biogen, other major drugmakers, the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or even a cure for the mind-robbing disease within a decade.

Updated March 17

Premium Lock Blackberry-IBM-Samsung secure tablet; Cablevision-HBO Now; GSK Ebola update; Facebook's buy; Lyft lawsuit

Bulldog In today's wrapup of technology and life science news: BlackBerry joins with IBM and Samsung to develop a secure tablet; GSK's Ebola vaccine advances; Cablevision hooks up with HBO Now; Facebook's latest buy; and did Lyft cheat drivers?

Techwire Inside Partners
The Skinny: A Blog by Rick Smith